Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Shares in Exopharm (EX1) have slumped after the company said it would cut back on spending in order to continue investing into its technologies and data generation
  • The reduction in spending comes in light of the poor sentiment surrounding the biotechnology sector and financial markets
  • A number of key executives have voluntarily cut back their salaries by 20 per cent, while all salary increases are currently on hold
  • In addition, the Board is currently exploring opportunities for new funding, including loan advances on its expected R&D Tax Incentive rebate
  • Exopharm is down 16.67 per cent to $0.15 per share as of 11:21 am AEST

Shares in Exopharm (EX1) have slumped after the company said it would cut back on spending in order to continue investing into its technologies and data generation.

The reduction in spending comes in light of the poor sentiment surrounding the biotechnology sector and financial markets.

A number of key executives have voluntarily cut back their salaries by 20 per cent, while all salary increases are currently on hold.

The company is reducing its international travel costs through a change in its travel policy and introducing more controls for financing non-core areas.

In addition, the Board is currently exploring opportunities for new funding, including loan advances on its expected R&D Tax Incentive rebate.

“The Board is working to extend the cash runway whilst maintaining core operations,” CEO Dr Ian Dixon said.

Exopharm is down 16.67 per cent to $0.15 per share as of 11:21 am AEST.

EX1 by the numbers
More From The Market Herald
The Market Herald Video

" Genmin (ASX:GEN) strikes royalty deal with Anglo American over Baniaka project, Gabon

Genmin (ASX:GEN) has struck a royalty agreement with Anglo American's subsidiary, Anglo American Marketing, over the…
The Market Herald Video

" Great Boulder Resources (ASX:GBR) hits “spectacular” intercept at Mulga Bill

Great Boulder Resources (ASX:GBR) has received assays from the final two diamond holes drilled at the…
The Market Herald Video

" ResApp (ASX:RAP) extends Medgate licence agreement in line with expansion plans

ResApp Health (ASX:RAP) has agreed to a 12 month extension to its commercial licence agreement with…
The Market Herald Video

" Indiana Resources (ASX:IDA) signs native title agreement to unlock exploration at Gawler Craton, SA

Indiana Resources (ASX:IDA) has signed a native title mining agreement with the Antakirinja Matu-Yankunytjatjara Aboriginal Corporation…